Profile
Avalon BioVentures is a venture capital firm based in La Jolla, California, specializing in biotech investments. Established over 40 years ago, the firm is led by Managing Partners Jay B. Lichter, Ph.D., Sanford J. Madigan, Ph.D., and Sergio G. Duron, Ph.D., who bring decades of experience in scientific research, operational management, and biotech investments. Avalon is known for its hands-on approach to nurturing early-stage biotech companies, providing operational support, strategic guidance, and leveraging their ABV Accelerator for company growth.
Avalon BioVentures focuses on pioneering life sciences and biotechnology, investing in early-stage developments and transformative therapeutic solutions. Their investment strategy includes identifying and developing disruptive biotech technologies, often partnering with world-class scientists and academic institutions. The firm typically invests in the pre-seed to Series A stage with a focus primarily on North America. In addition to the newly announced $200m Avalon BioVentures II, their investment history includes other successful fund iterations.
Notable portfolio companies include Janux Therapeutics - cancer immunotherapy, Synthorx - protein therapeutics (acquired by Sanofi for $2.5 billion), and Fortis Therapeutics - cancer treatments. Avalon’s approach involves not just financing but also participating in the corporate governance and strategic decisions of its portfolio companies, driving them towards successful exits like IPOs and acquisitions.
Industry
Avalon BioVentures Funds
| Name | Type |
|
|
|
Size | AUM | Launch date |
|---|---|---|---|---|---|---|---|
|
Avalon BioVentures II, LP
|
Venture Capital (VC)
|
Biotechnology
|
Pre-seed
Seed
Series A
|
North America
|
$1-5 m
|
$200 M
|
November 2026
|
Contacts
Instant access on the web. Plans from $129/month — see pricing.